18
2021-05
Dr. Bernard A. Fox Appointed the Member of Scientific Advisory Committee of CanWell
CanWell announced today that Dr. Bernard A. Fox is appointed as the Advisor of CanWell’s Scientific Advisory Committee (SAC). Dr. Fox is a leading researcher in the field of cancer immunotherapy and currently serves as the Chief and Director of the Molecular and Tumor Immunology Laboratory at the Ea…
22
2021-03
CanWell, Sun Yat-sen Memorial Hospital of Sun Yat-sen University and UbiVac Jointly Held a Clinical Seminar on Cancer Vaccine DPV-001
Sun Yat-sen Memorial Hospital of Sun Yat-sen University, together with CanWell and UbiVac, Inc., successfully held the International Symposium on Clinical Trials of Cancer Vaccine DPV-001 Vaccine. CanWell has obtained the exclusive license of UbiVac immunotherapy cancer vaccine DPV-00…
25
2021-02
CanWell and UbiVac Announce Exclusive License Agreement For Cancer Vaccine DPV-001 in Greater China
CanWell Pharma Inc., a leading venture-backed biopharmaceutical company developing innovative immunotherapies for cancer, and UbiVac, Inc., a US clinical stage immunotherapy company, today announced an exclusive license agreement to develop and commercialize UbiVac’s cancer vaccine DP…